Aviance Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Aviance Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-146	Closed	-$486K	–	322
2014 Q4	$486K	Buy	146 +17	+13%	+$52.1K	0.02%	234
2014 Q3	$373K	Buy	129 +20	+18%	+$66.2K	0.02%	250
2014 Q2	$413K	Buy	109 +9	+9%	+$33.9K	0.02%	240
2014 Q1	$543K	Buy	100 +97	+3,233%	+$511K	0.03%	198
2013 Q4	$9K	Buy	+3	New	+$9.25K	﹤0.01%	365

Other funds holding NBSE

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Aviance Capital Management's NBSE Position: Q1 2015 in Review

Aviance Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2015, closing a stake of 146 shares — an estimated $486K sold.

Aviance Capital Management first reported a position in NBSE in Q4 2013 and held it in 5 quarters. The position peaked at $543K in Q1 2014. 64 funds tracked by Wall St. Rank hold NBSE as of Q1 2015.

Aviance Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2015 after selling out during the quarter.
Aviance Capital Management sold 146 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2015, an estimated $486K.
Aviance Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2013 and held it in 5 quarters.
Aviance Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $543K in Q1 2014.
64 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2015.

Based on Aviance Capital Management's 13F filing for Q1 2015, filed 14 May 2015.